SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Verve Therapeutics, Inc. (Nasdaq – VERV)
BALA CYNWYD – June 17, 2025/Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Verve Therapeutics, Inc. (“Verve Therapeutics” or the “Company”) (Nasdaq – VERV) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Eli Lilly and Company (“Lilly”) (NYSE – LLY). Under the terms of the transaction, Lilly will commence a tender offer to acquire all of the outstanding shares of Verve for a purchase price of $10.50 per share in cash (an aggregate of approximately $1.0 billion) payable at closing, plus one non-tradeable contingent value right (CVR) per share that entitles the holder to receive up to an additional $3.00 per share, for a total potential consideration of up to $13.50 per share in cash without interest (an aggregate of up to approximately $1.3 billion).
The investigation concerns whether the Verve Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal provides fair value to the Company’s shareholders.
If you own shares of Verve Therapeutics stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at clients@brodsky-smith.com, or call toll free 855-576-4847.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.